The ID (insertion/deletion) polymorphism of the ACE (angiotensin-converting enzyme) gene controls plasma ACE levels. Both have been correlated with ISR (in-stent restenosis) in preliminary analyses, but not confirmed in larger studies. In the present study, baseline and 6-month quantitative coronary analysis were performed in 897 patients who had stent implantation and the ID polymorphism genotyped. Plasma ACE levels were measured in 848 patients (95 %). Restenosis rates among genotypes were 31.2 % DD, 25.5 % ID and 28.8 % II (not significant). Plasma ACE levels were significantly higher in restenotic patients compared with patients without restenosis (30.7 + − 18.6 units/l compared with 22.8 + − 12.8 units/l; P = 0.0001) and a strong independent predictor of ISR [OR (odds ratio) = 3.70; 95 % CI (confidence interval), 2.40-5.71; P < 0.0001], except in diabetics. In the subgroup of diabetics and patients with AMI (acute myocardial infarction), the DD genotypes actually had a lower risk of ISR than the II genotypes (diabetics, OR = 0.16; 95 % CI, 0.04-0.69; P = 0.014; and patients with AMI, OR = 0.21; 95 % CI, 0.061-0.749; P = 0.016). After exclusion of diabetics and patients with AMI, ISR rates for genotypes in 632 patients were 31.7 % DD, 24.3 % ID and 17.6 % II (P = 0.02; DD compared with non-DD OR = 1.57; 95 % CI, 1.09-2.25). The association between the D allele and ISR observed in selected populations does not hold with a larger sample size. Other than sample size, clinical variables can modulate the association between ID polymorphism and ISR. Plasma ACE level is a risk factor for ISR, independently of the ID genotype.
INTRODUCTION
The deletion allele of the ID (insertion/deletion) polymorphism of the ACE (angiotensin-converting enzyme) gene has been found to predict the occurrence of ISR (in-stent restenosis) in two similar populations studied in France [1] and Italy [2] . Following these initial observations, two larger studies performed in Germany [3] and Denmark [4] yielded negative results, casting doubts about the predictive value of the ID polymorphism in this process. The study of the ID polymorphism as a marker of risk for restenosis after balloon angioplasty resulted in similarly contradictory findings between a small positive study [5] and subsequent negative larger investigations [6] . Recently, a metaanalysis has assessed the value of the D allele as a marker for restenosis. Although an increased risk of ISR was observed in D allele carriers, this was smaller than initially reported, showing evidence for possible publication and sample size bias [7] . In fact, negative results may be less likely to be published, and small sample-sized studies are more prone to bear some statistical inconsistency. However, differences between studies of restenosis may depend not only on the sample size, but also on clinical or angiographic variables that may not be apparent at first sight [8, 9] . To determine the relevance of clinical variables, uniform prospective cohorts containing a large number of patients are needed in order to obtain reliable statistical comparisons between subgroups.
When interpreting restenosis studies it is worth noting that the mechanisms leading to ISR differ from those involved in restenosis after balloon angioplasty [10] , an important concept that was obviated in the reported meta-analysis [7] . In fact, the enhanced activity of RAS (renin-angiotensin system) may be related to the proliferative response that follows stent implantation, but not to the vessel wall remodelling that causes restenosis after balloon injury [2] . The D allele of the ID polymorphism of the ACE gene correlates with higher plasma levels of the enzyme, and this makes the D allele a candidate marker of ISR being related to the raised levels of angiotensin-II and to the decreased levels of bradykinin. However, whether this mechanism plays a role in the development of ISR in humans is controversial [1] [2] [3] [4] 7] . Discrepancies may lie in differences between experimental models of restenosis and restenosis in humans, and in differences among human studies. The role of RAS in the process of vascular wall repair after injury in animal models of restenosis [11, 12] and the correlation between the D allele and plasma level of ACE in humans have been well established [13, 14] . We reported previously [2, 14] that RAS activity, assessed by the determination of plasma ACE, may be relevant for human ISR, and that the ID polymorphism can be a marker of this activity; however, this issue remains unclear.
The aim of the present study is to analyse the value of the ID polymorphism and of the plasma ACE levels as predictors of ISR in a large series of non-selected patients that, unlike previous positive reports, are more representative of daily practice and less likely to be biased by small sample size. Furthermore, associations between the two markers and some patients characteristics are explored to understand better their clinical relevance.
METHODS
The occurrence of angiographic ISR was analysed in 897 patients (treated on 998 lesions) whose ID polymorphism genotypes and adequate QCA (quantitative coronary analysis) pre-and post-intervention and at 6-month follow-up have been assessed. They belong to a series of patients who underwent coronary angioplasty with bare metal stent implantation in all cases and ACE genotyping (85 %) and were scheduled for elective repeat QCA between 1993 and 2000. The aim of this data collection was to investigate the role of different genetic polymorphisms as risk factors for ISR. The study was performed according to Institutional Guidelines, and patients gave informed consent to the diagnostic and interventional procedures.
Coronary angioplasty and stenting were performed with conventional techniques. QCA was performed before balloon angioplasty, after high-pressure stent implantation and at follow-up coronary angiography using an on-line system (Philips DCI). Images of lesions were displayed in at least two orthogonal projections after administration of 0.5 mg of intracoronary nitroglycerine. Measurements were made with the DCI Host Automated Coronary Analysis package. D-ref (reference diameter), MLD (minimum lumen diameter) and %DS (percentage diameter stenosis) were calculated as the mean of values obtained in two orthogonal views. Follow-up angiography used the same projections as the original procedure. Acute gain was defined as the increase in MLD achieved immediately after high-pressure coronary stenting. Late loss was defined as the decrease in MLD of the same segment observed on the follow-up angiogram. The net gain was the difference between the acute gain and the late loss. The definition of restenosis was %DS 50 % at the site of the lesion treated with the stent(s) observed in at least one of two orthogonal projections, one of which always including the 'worst view' of the segment being analysed. QCA was performed without knowledge of the biochemical and genetic data of the patient and vice versa. Most of the missing QCA followup (15 %) were due to advanced age, impaired general condition or patient's preference not to repeat angiography systematically.
In 848 out of the 897 patients (95 %), the plasma ACE concentration (units/l) was determined using FAPGG (fluril-acriloil-fenilalanilglycilglycina) substrate (Sigma Diagnostics) at the moment of the procedure and was available for analysis. Details of the methods for ID genotyping, plasma determination of ACE and other biochemical values were as reported previously [2] in a cohort of 176 subjects, who are included in the present analysis.
Patient population
The mean age was 61 + − 10 years, 737 (82.2 %) were males, 350 (39 %) had stable angina or silent ischaemia, 386 (43 %) had unstable angina and 161 (18 %) had AMI (acute myocardial infarction); 125 (14 %) were diabetics, 407 (45.4 %) were hypertensive and 581 (64.8 %) had a prior myocardial infarction. No exclusion criteria were applied for the assessment of restenosis in this series. The same patients reported in the present manuscript have been analysed according to the use of ACE-inhibitors as reported previously [15] . . Acute and followup QCA parameters were correlated with plasma ACE levels and tested for statistical significance. QCA parameters were transformed to avoid possible skewness in their distribution. Log-transformation was used for all variables except for %DS which, as a percentage, has been transformed in arcsin √ %DS, the angular transformation which makes constant the sampling error of a percentage whatever its value. Kruskal-Wallis nonparametric one-way ANOVA was used to evaluate differences within ACE genotypes and the least-significant difference multiple comparison test (at a significance level of 0.05) was used to detect statistically significant differences of continuous parameters between genotypes. A logistic multivariate model was tested to assess the predictive value of factors related to ISR. The parameters of the model included gender, age, hypertension, diabetes, previous infarction, hypercholesterolaemia, plasma ACE level, family history of CAD (coronary artery disease), smoking, acute coronary syndromes, previous angioplasty, angiographic type lesion, multiple stent implantation, length of the stented lesion and vessel diameters calculated by QCA. Based on previous observations [1, 2] , a sample size of 340 patients/group was deemed sufficient to prove/exclude a 25 % difference in the incidence of restenosis between DD patients (expected restenosis rate 32 %) and non-DD patients (expected rate 24 %) with a statistical power 1 − β = 90 %. According to the distribution of the ID polymorphism in Caucasians, nearly 900 patients were needed to screen 340 DD patients. All the analyses have been performed using the SPSS statistical package (software version 9.0 for Windows).
Statistical analysis

RESULTS
At follow-up angiography, 254 out of 897 patients had ISR (28.3 %). Per-lesion analysis showed 271 restenotic lesions out of 998 stented lesions (27.2 %). Mean time to follow-up was 6.3 + − 2.5 months.
The clinical and angiographic variables of the 897 patients and their 998 lesions presented for genotyping are shown in Table 1 . The allele frequency distribution was in Hardy-Weinberg equilibrium and the time to follow-up was similar for the three genotype groups.
Variance in plasma ACE levels
Plasma ACE level differed significantly according to the ID polymorphism in the 586 patients not receiving ACE-inhibitors who had plasma ACE determinations at baseline (DD, 33.0 + − 17.0 units/l; ID, 22.1 + − 10.8 units/l; II, 12.6 + − 5.9 units/l; P < 0.0001), but not in the 262 patients receiving ACE-inhibitors (DD, 5.3 + − 6.8 units/l; ID, 5.4 + − 6.4 units/l; II, 4.0 + − 4.7 units/l; P value not significant).
The measurement of plasma ACE levels in patients not receiving ACE-inhibitors allowed the determination of the fraction of ACE level variance explained by the ID polymorphism. In a previous study [2] , an optimal cut-off value for the plasma ACE level was calculated by maximizing the specificity for predicting restenosis, the resulting value of 34 units/l predicted occurrence and no occurrence of restenosis in 65 % and 92 % of the cases respectively. Using the same threshold value in the patients not receiving ACE-inhibitors, 96 (42.3 %) out of 227 DD patients, 37 (12.6 %) out of 294 ID patients and none of the 94 II patients had 'high' enzyme levels.
Univariate analysis of restenosis
The occurrence of restenosis at the follow-up QCA analysed as a categorical variable correlated with the use of multiple stents [OR (odds ratio) = 2.67; 95 % CI (confidence interval), 1.77-4.03; P < 0.00001], diabetes (OR = 2.48; 95 % CI, 1.68-3.65; P < 0.00001), the presence of a previous restenosis (OR = 2.57; 95 % CI, 1.39-4.77; P = 0.003) and hypertension (OR = 1.45; 95 %CI, 1.08-1.94; P = 0.013). Considering continuous variables, an increased risk of ISR per unit of measure was observed for the reference vessel diameter (OR = 0.47; 95 % CI, 0.35-0.64; P < 0.00001) and MLD (OR = 0.66; 95 % CI, 0.47-0.91; P = 0.011) before and after (OR = 0.51; 95 % CI, 0.37-0.70; P < 0.0001) the procedure, and the length of the stented lesion (OR = 1.04; 95 % CI, 1.02-1.06; P < 0.0001). The basal plasma level of ACE was confirmed as a strong predictor of ISR in patients not receiving ACE-inhibitors either as a continuous (OR = 1.03; 95 % CI, 1.02-1.04; P < 0.0001) or a categorical (OR = 3.73; 95 % CI, 2.47-5.64; P < 0.0001) variable.
Plasma ACE levels and restenosis
Patients with high basal plasma ACE levels ( 34 units/l) had a 45.1 % restenosis rate (60 out of 133) compared with 18 % (87 out of 482) in patients with low plasma . Although no II patient had plasma ACE levels 34 units/l, basal enzyme levels of II patients with ISR tended to be higher than in non-restenotic patients (14.1 + − 7.6 units/l compared with 11.5 + − 5.3 units/l respectively; P = 0.09). The mean basal plasma ACE level in patients with restenosis at follow-up was 30.7 + − 18.6 units/l compared with 22.8 + − 12.8 units/l in patients without restenosis (P = 0.0001). A significantly higher enzyme level was also observed in restenotic patients of all subgroups, except in diabetics (Table 2) .
Plasma ACE levels, ID polymorphism and restenosis
When all 897 patients were considered, plasma ACE levels, but not the D allele of the ACE gene, were significantly correlated with MLD, late lumen loss, net gain and %DS at follow-up (Table 3) . Compared with our previous study [2] , this large non-selected group included ACE-inhibited, diabetic (including those with insulindependent diabetes) and AMI patients. In the subgroup In addition, in our previous analysis [2] , patients with AMI (18 %) were excluded. In this subset, the mechanisms of restenosis could be different from those of elective angioplasty, as suggested by the lower restenosis rate reported after primary angioplasty [16] . Primary or rescue stent implantation was performed on 161 patients. The restenosis rate, MLD,%DS and late loss for genotype were as follows: restenosis rate (DD, 25. To test whether the discrepancy of the present findings with those of our previous report [2] is possibly due to the clinical heterogeneity of the sample, the 125 diabetic patients and those treated with primary or rescue PTCA (percutaneous transluminal coronary angioplasty) where excluded from the analysis, and a total of 632 patients (70 % of the total cohort) were therefore considered. Table 4 shows the relationships among follow-up QCA results, plasma ACE levels and ID genotypes in this more selected, but less heterogeneous, subsample of elective stenting in non-diabetic patients. In this case, the D allele was associated significantly with the occurrence of ISR (DD, 31.7 %; ID, 24.3 %; II, 17.6 %; P = 0.02; DD versus non-DD, OR = 1.57; 95 % CI, 1.09-2.25; DD versus ID, OR = 1.45; 95 % CI, 0.99-2.11; and DD versus II, OR = 2.17; 95 % CI, 1.16-4.04). Correlation with ACE level also remained highly significant in this subsample.
Multivariate analysis
A multivariate model was applied to assess the predictive value of factors related to ISR in all patients. The model was created as described in the Methods section. Independent predictors of ISR were the high plasma ACE levels (OR = 3.70; 95 % CI, 2.40-5.70; P = 0.0001), the implantation of multiple stents (OR = 2.64; 95 % CI, 1.67-4.18; P = 0.0001), diabetes (OR = 2.36; 95 % CI, 1.55-3.60; P = 0.0001), the reference vessel diameter after angioplasty (OR = 0.43; 95 % CI, 0.30-0.62; P = 0.0001) and the type of coronary lesions (OR = 0.33; 95 % CI, 0.17-0.65; P = 0.001). When patients with diabetes and AMI were excluded, the analysis of the remaining 632 patients revealed that high plasma ACE levels (OR = 4.20; 95 % CI, 2.62-6.73; P = 0.0001), the reference vessel diameter after angioplasty (OR = 0.42; 95 % CI, 0.28-0.63; P = 0.0001), a previous restenosis (OR = 2.79; 95 % CI, 1.24-6.29; P = 0.014) and the type of coronary lesion (OR = 0.47; 95 % CI, 0.27-0.84; P = 0.011) were independent predictors of ISR. The D allele of the ACE gene was not an independent predictor, probably because of its apparent correlation with plasma ACE levels. Plasma ACE levels mask the effect of the D allele as the effect on restenosis is not additive and, therefore, cannot be singled out as an independent predictor.
DISCUSSION
In the present study, we have shown that the D allele of the ID polymorphism of the ACE gene is not predictive of the occurrence of ISR in a large series of non-selected patients. This finding, like other larger series [3, 4] , seems to contradict previous analyses [1, 2] . The present study demonstrates that positive genetic associations obtained in small and selected cohorts may not be replicated in larger non-selected cohorts of the same population, a finding that should be taken into very careful consideration for future genetic association studies. In fact, when confounding factors associated with ISR are limited, as in our initial experimental design, then the genetic effect of the D allele of the ACE gene is likely to be more clearly dissected. This important finding suggests that discrepancies between large series and smaller initial reports may depend not only on the sample size, but also on clinical features not analysed in preliminary assessments when subgroups are either excluded or limited to a few cases. Another important conclusion of the present study investigation is that the role of the plasma ACE level as a major risk factor for ISR identified in a previous analysis [2] is fully confirmed.
The ID polymorphism of the ACE gene is a functional marker of RAS activity, enhanced plasma ACE levels are marked accordingly by the presence of the D allele which, in some subjects, exerts a co-dominant genetic effect on the phenotype; however, the genetic variance of this marker is lower than 40 % [13] . In the present study, the plasma ACE levels measured by genotype are in agreement with those reported in other Caucasian populations [9, 13] and identical with the values reported previously in smaller sample sizes [2, 14] . Also, the fraction of the ACE level variance explained by the ID polymorphism in the present study replicates that reported previously on selected patients; indeed, high levels of the enzyme were found in 42.3 % of DD and 12.6 % of ID patients and such patients had similar high restenosis rates (43.8 and 48.6 % respectively). This suggests that, if plasma ACE is involved in ISR, the D allele of the ID polymorphism cannot identify all these patients. Interestingly, although no II patient had high plasma ACE levels, the mean value of the enzyme still tended to be higher in II patients with restenosis, which suggests that RAS (or perhaps ACE itself) also plays a role in subjects in which the D allele is not a marker of its activity. The present findings therefore support the conclusion expressed in our original report that "plasma ACE activity itself may be a more direct marker of the risk of stent restenosis than the ACE genotype" [2] . However, the relationship between the ID polymorphism and ISR may change in clinical subsets, for instance in diabetics or in patients with AMI, weakening somewhat its value as a marker of individual predisposition to ISR in clinical practice. Conversely, plasma ACE levels remain an interesting candidate risk factor for ISR that deserves further investigation, possibly in the direction of other candidate genes contributing to its expression.
The finding of a lack of association of the ID polymorphism and plasma ACE levels with ISR in diabetic patients could be related to the different cellular mechanisms of restenosis [17] , in which RAS may not be a determinant, or to different biological mechanisms leading to restenosis in this population. For example, robust evidence indicates that the I allele of the ACE gene correlates with insulin resistance, whereas the D allele correlates with insulin sensitivity [18] [19] [20] , and insulin resistance is likely to play a relevant role in restenosis in diabetic patients. Restenosis in AMI patients may also respond to different biological mechanisms; indeed, platelet aggregation and thrombus formation may play a more determinant role than cellular proliferation, and this appears to be independent of the ID polymorphism and ACE level.
If clinical presentation could influence the value of a genetic marker of ISR, then previous investigations should be analysed in the light of these new observations. Compared with the two positive studies relating the D allele and ISR [1, 2] , the negative study by Koch et al. [3] had a larger sample size, but also a much higher incidence of diabetes (> 20 %), stent implantation in AMI (> 25 %) and restenotic lesions (> 23 %). These authors [3] showed in a subsequent analysis of the same patients that the stent design is one of the strongest determinants of ISR [21] and several stent types were used in their genetic report [3] . Other important differences may derive from the large use of ACE-inhibitors (> 50 %) or abciximab (20 %), and the relatively low incidence of unstable angina (< 30 %) in this population [3] . On the other hand, in the study by Amant et al. [1] and in our previous study [2] , there were no AMI procedures or restenotic lesions, and no patient was treated with abciximab. Furthermore, in our first report [2] , the use of stents was limited to the sole Palmaz-Schatz stent type, there was a much higher incidence of unstable angina (50 %), a very low incidence of diabetes (< 10 %) without insulin-dependent patients and no patient received ACE inhibitors.
In the present study, the risk of developing ISR for elective non-diabetic DD patients with vessels 3.0 mm is 2.80 (95 % CI, 1.22-6.43; P = 0.02), very similar to the risk described in our previous study [2] for patients with these 'low-risk' characteristics, confirming the role of the D allele in ISR in these cases. However, a higher restenosis rate was observed in the II group. Differences in patients characteristics, such as the smaller size of the treated vessels (made possible with new generation stents), a higher incidence of diabetes in II patients (Table 1) or the wide use of ACE-inhibitors [15] , could influence the distribution of ISR among genotypes significantly.
Other less obvious factors may account for the variability observed in different studies; among these, two are worth considering. The first is the variable degree of linkage disequilibrium that a genetic polymorphism may have in different ethnic groups and the interactions that the polymorphism may have with a changing environment [7] [8] [9] 22] . In fact, in the present study, DD patients still show higher ISR rates compared with the other genotypes, whereas this is not the case for German and Danish patients [3, 4] . The second consideration regards the pharmacological treatment introduced in current medical care in the last few years that can affect the long-term outcome of percutaneous revascularization procedures. Indeed, many patients are now treated routinely with drugs that have an impact on the process of ISR, although such effects were not know previously. For example, statins [23] , ticlopidine [24] and IIb-IIIa glycoprotein inhibitors in diabetic patients [25] have been shown to reduce significantly the need for re-intervention after stented angioplasty. The actions of these drugs may be able to blunt the effect of a single genetic factor [22] , as has been demonstrated for statins in patients carrying the A2 allele of the Pl A2/A1 polymorphism of the glycoprotein IIIa gene [26] .
In an attempt to forecast the occurrence of ISR after coronary interventions, predictive models based on angiographic, clinical and procedural variables have been proposed [27] . Although the identification of markers of increased susceptibility to restenosis may be helpful, research into clinically meaningful genetic markers of ISR is still rather elusive. The case of the ID polymorphism of the ACE gene shows how the genetic heterogeneity derived from the complexity of the multifactorial restenotic process is not likely to be related to a single polymorphism, but rather to several functional polymorphisms that may be expressed in the same gene locus or, more probably, in different loci. In any case, the relationship between high levels of plasma ACE and ISR may still be a useful tool to dissect relevant genetic markers of RAS potentially involved in ISR.
However, with its contrasting findings, the study of the ID polymorphism in interventional cardiology is a good example of how initial speculations can develop as 'hypothesis-generating' sources. Indeed, the preliminary studies allowed the identification of plasma ACE as a risk factor for ISR and also the testing of the concept of 'pharmacogenetics' as applied, for example, in the PARIS trial [28] , an elegant study that, with its intriguing experimental findings supported by clinical observations [15] , opened unexpected research perspectives in the field of ACE inhibition.
On one hand, exploratory reports may lead to innovative hypotheses which should not be disregarded; on the other, subsequent, more comprehensive, studies are required to validate the clinical relevance of preliminary genetic association studies.
Limitations of the study
Subgroups analysis is an exciting way to determine the importance of a genetic marker in different clinical contexts. It should be founded on a prespecified hypothesis and requires a large sample size analysed by multicomparison rules with thresholds of significance corrected by the number of comparisons done to avoid the risk of obtaining futile results. The present study confirms the risk of restenosis conferred by the D allele of the ID polymorphism in a non-selected population, with the exception of diabetics and AMI patients. Other subgroup analysis (such as by gender, stent type, vessel size etc.) would be interesting, but may result in spurious conclusions. Furthermore, the lack of a centralized independent core laboratory is an important limitation of all the studies that, like ours, have investigated the relationship between restenosis and genetic markers.
